GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Debt-to-Asset

Paradigm Biopharmaceuticals (ASX:PAR) Debt-to-Asset : 0.01 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Debt-to-Asset?

Paradigm Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.11 Mil. Paradigm Biopharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.18 Mil. Paradigm Biopharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$45.04 Mil. Paradigm Biopharmaceuticals's debt to asset for the quarter that ended in Dec. 2023 was 0.01.


Paradigm Biopharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Debt-to-Asset Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial - 0.01 0.01 0.01 0.01

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 - 0.01 0.01

Competitive Comparison of Paradigm Biopharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Debt-to-Asset falls into.



Paradigm Biopharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Paradigm Biopharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Paradigm Biopharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paradigm Biopharmaceuticals  (ASX:PAR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Paradigm Biopharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).